Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $33.1667.

Several research firms recently issued reports on UPB. HC Wainwright started coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. downgraded Upstream Bio from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $35.00 to $8.00 in a research report on Friday, June 12th. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a research note on Friday, March 27th.

Institutional Investors Weigh In On Upstream Bio

A number of hedge funds have recently added to or reduced their stakes in UPB. Integral Health Asset Management LLC acquired a new position in shares of Upstream Bio in the third quarter worth $10,816,000. Jennison Associates LLC acquired a new stake in shares of Upstream Bio in the fourth quarter valued at $7,842,000. Pictet Asset Management Holding SA purchased a new position in Upstream Bio in the fourth quarter valued at $20,991,000. UBS Group AG boosted its holdings in Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares during the period. Finally, Simplify Asset Management Inc. acquired a new position in Upstream Bio during the 1st quarter worth $700,000.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $7.51 on Monday. The firm has a market cap of $408.69 million, a price-to-earnings ratio of -2.58 and a beta of 1.23. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $33.68. The business’s 50 day moving average is $7.79 and its two-hundred day moving average is $14.53.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.03 million. Analysts anticipate that Upstream Bio will post -2.9 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.